Summary:
«Berlin-based medical AI company Ada Health has announced the launch of a new partnership with Novartis in order to speed up the diagnosis for patients with immunological diseases and rare conditions.»
«One of the conditions that Ada and Novartis are focused on is axial spondyloarthritis (axSpA), along with psoriatic arthritis (PsA) and familial Mediterranean fever (FMF). Axial Spondyloarthritis is a chronic inflammatory disease that can lead to chronic pain, structural damage and disability. Affecting around one in 200 adults, axSpA is notoriously difficult to identify. Timely diagnosis is a critical factor for a patient’s future quality of life but symptoms can present in many ways and be indicative of other conditions. Worldwide, the delay to diagnosis averages about five years – with women taking two years longer than men to be diagnosed.»
Article written by Sara Mageit – Image by Ada Health / Novartis
13|06|2021
Source:
Mobi Health News